Ruben Boon

Dr. Ruben Boon

KU Leuven - Department of Human Genetics
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Nature
Verified
Journal Article
Closed access
PDF file
KVKim Vriens
Kim Vriens
SCStefan Christen
Stefan Christen
SPSweta Parik
Sweta Parik
DBDorien Broekaert
Dorien Broekaert
KYKazuaki Yoshinaga
Kazuaki Yoshinaga
SFSarah-Maria Fendt
Sarah-Maria Fendt

11 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
Wenting GuoWenting Guo
Wenting Guo
MNMaximilian Naujock
Maximilian Naujock
LFLaura Fumagalli
Laura Fumagalli
TVTijs Vandoorne
Tijs Vandoorne
PBPieter Baatsen
Pieter Baatsen
LBLudo Van Den Bosch
Ludo Van Den Bosch
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder due to selective loss of motor neurons (MNs). Mutations in the fused in sarcoma (FUS) gene can cause both juvenile and late onset ALS. We generated and characterized induced pluripotent stem cells (iPSCs) from ALS patients with different FUS mutations, as well as from healthy controls. Patient-derived MNs show typical cytoplasmic FUS pathology, hypoexcitability, as well as progressive axonal transport defects. Axonal transport defects are rescued by CRISPR/Cas9-mediated genetic correction of the FUS mutation in patient-derived iPSCs. Moreover, these defects are reproduced by expressing mutant FUS in human embryonic stem cells (hESCs), whereas knockdown of endogenous FUS has no effect, confirming that these pathological changes are mutant FUS dependent. Pharmacological inhibition as well as genetic silencing of histone deacetylase 6 (HDAC6) increase α-tubulin acetylation, endoplasmic reticulum (ER)–mitochondrial overlay, and restore the axonal transport defects in patient-derived MNs.

11 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
IEIlaria Elia
Ilaria Elia
DBDorien Broekaert
Dorien Broekaert
SCStefan Christen
Stefan Christen
RBRuben Boon
Ruben Boon
EREnrico Radaelli
Enrico Radaelli
SFSarah-Maria Fendt
Sarah-Maria Fendt
Metastases are the leading cause of mortality in patients with cancer. Metastasis formation requires cancer cells to adapt their cellular phenotype. However, how metabolism supports this adaptation of cancer cells is poorly defined. We use 2D versus 3D cultivation to induce a shift in the cellular phenotype of breast cancer cells. We discover that proline catabolism via proline dehydrogenase (Prodh) supports growth of breast cancer cells in 3D culture. Subsequently, we link proline catabolism to in vivo metastasis formation. In particular, we find that PRODH expression and proline catabolism is increased in metastases compared to primary breast cancers of patients and mice. Moreover, inhibiting Prodh is sufficient to impair formation of lung metastases in the orthotopic 4T1 and EMT6.5 mouse models, without adverse effects on healthy tissue and organ function. In conclusion, we discover that Prodh is a potential drug target for inhibiting metastasis formation.

27 February 2019 in Nature
Verified
Journal Article
Closed access
PDF file
IEIlaria Elia
Ilaria Elia
MRMatteo Rossi
Matteo Rossi
SSSteve Stegen
Steve Stegen
DBDorien Broekaert
Dorien Broekaert
GDGinevra Doglioni
Ginevra Doglioni
SFSarah-Maria Fendt
Sarah-Maria Fendt

8 February 2016 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
CLChristian Lange
Christian Lange
MGMiguel Turrero Garcia
Miguel Turrero Garcia
IDIlaria Decimo
Ilaria Decimo
Francesco BifariFrancesco Bifari
Francesco Bifari
GEGuy Eelen
Guy Eelen
PCPeter Carmeliet
Peter Carmeliet

1 July 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
MCMar Coll
Mar Coll
LPLuis Perea
Luis Perea
RBRuben Boon
Ruben Boon
SLSofia B. Leite
Sofia B. Leite
JVJulia Vallverdú
Julia Vallverdú
PSPau Sancho-Bru
Pau Sancho-Bru